interesting, but I doubt they foresaw the FDA holdup. It seems like a prudent topic / clause to include for both parties given the FDA decision was close & not known. SPL probably wanted separate payment clauses to maximise payment and spread the risk as much as ITF.
SPL will get paid for prevention and treatment approvals separately, which is good to know in the current situation.
Meaning of 2 indications in Starpharma VivaGel announcement of 20-12-2018, page-4
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |